Purple Biotech Raises $2M from Warrant Exercise
Ticker: PPBT · Form: 6-K · Filed: Jul 1, 2024 · CIK: 1614744
Sentiment: neutral
Topics: financing, warrants
TL;DR
Purple Biotech just cashed in $2M from warrants, adding fuel to the fire.
AI Summary
On July 1, 2024, Purple Biotech Ltd. announced the exercise of warrants, resulting in gross proceeds of $2 million. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel.
Why It Matters
This capital infusion provides Purple Biotech with additional funds, potentially for ongoing research and development or operational expansion.
Risk Assessment
Risk Level: medium — The company's financial health and future prospects depend on successful warrant exercises and the overall performance of its biotechnology products.
Key Numbers
- $2.0M — Gross Proceeds (From exercise of warrants announced on July 1, 2024.)
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- $2 million (dollar_amount) — Gross proceeds from warrant exercise
- July 1, 2024 (date) — Date of press release
- Kitov Pharma Ltd. (company) — Former company name
FAQ
What is the total amount of gross proceeds Purple Biotech Ltd. announced from the exercise of warrants?
Purple Biotech Ltd. announced gross proceeds of $2 million from the exercise of warrants.
On what date did Purple Biotech Ltd. issue the press release regarding the warrant exercise?
The press release was issued on July 1, 2024.
What was Purple Biotech Ltd. formerly known as?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
Where is Purple Biotech Ltd. located?
Purple Biotech Ltd. is located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
What form is this filing?
This filing is a Form 6-K, Report of Foreign Private Issuer.
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-07-01 09:05:14
Key Financial Figures
- $2 Million — tech Announces Exercise of Warrants for $2 Million Gross Proceeds, ” a copy of which
Filing Documents
- ea0208785-6k_purple.htm (6-K) — 14KB
- ea020878501ex99-1_purple.htm (EX-99.1) — 14KB
- 0001213900-24-057584.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. July 1, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2